November 19, 2024 8:13am
Even though I might be going against the trend and experience “some” loss
5 negative closes in a row within 12 November negative closes makes a case for the oversold
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
MY Pre-Open Thoughts: 5 Positive, 2 Negative Indications and 1 Sell into Strength
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
RegMed Investors (RMi) Closing Bell: Buy-into sector after political “concerns” spool value downward … https://www.regmedinvestors.com/articles/13702
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628
Tuesday: The pre-open Dow futures are DOWN -0.45% (-196 points), the S&P futures are DOWN -0.24% or (-14 points) and the Nasdaq futures are DOWN -0.09% or (-19 points)
- Stock futures were lower early Tuesday as geopolitical tensions weighed on sentiment,
- European markets slid,
- Asia-Pacific markets rose.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Monday: The Dow closed DOWN -55.39 points or -0.13%, the S&P closed UP +23 points or +0. l39% while the Nasdaq closed UP +111.68 points or +0.60%
- Monday’s advance/decline line ended with a negative close at the close of 14 incliner, 20 decliners and 1 flat
Economic Data Docket: Housing starts month-over-month, October (-1.4% expected, -0.5% previously); Building permits, month-over-month, October (1.2% expected, -3.1% previously)
Q4/24: November 8 negative and 4 positive closes
- October: 8 positive and 15 negative closes
Q3/24:
- September – 10 positive and 10 negative close
- August – I neutral, 10 positive and 11 negative closes
- July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Sell into Strength:
Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Mesoblast (MESO) closed up +$0.60 after Friday’s -$1.28 after Thursday’s -$0.39, Wednesday’s +$1.76 after Tuesday’s +$0.22 after Monday’s +$0.55 with a neutral pre-market
Positive Indications:
Monday, Friday, Thursday, Wednesday, Tuesday after last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Alnylam Pharmaceuticals (ALNY) closed down -$22.35 after Thursday’s -$5.56, Wednesday’s -$4.35, Tuesday’s -$10.87 and Monday’s +$2.39 with a positive +$0.73 or +0.31% aftermarket
Ultragenyx Pharmaceuticals (RARE) closed down -$0.97 after Friday’s -$2.89 after Thursday’s -$1.07, Wednesday’s +$0.87 and Tuesday’s -$2.89 with a neutral pre-market
CRISPR Therapeutics (CRSP) closed up +$0.05 after Friday’s +$0.40, Thursday’s -$2.94, Wednesday’s -$0.94, Tuesday’s -$4.13 and last Monday’s +$3.24 with a positive +$0.06 or +0.13% aftermarket
Intellia Therapeutics (NTLA) closed up +0.20 after Friday’s -$1.15, Thursday’s-$0.99, Wednesday’s -$0.54, Tuesday’s -$0.85 and last Monday’s +$0.77 with a negative -$0.03 or -0.21% pre-market. NTLA unveiled promising P1 clinical trial results for Nexiguran Ziclumeran, a CRISPR-based gene-editing therapy aimed at treating transthyretin amyloidosis. The therapy demonstrated significant reduction in serum TTR levels and showed stabilization or improvement in disease markers over 12 months. The trial highlights Nexiguran’s potential as a one-time treatment option, with favorable safety and tolerability, providing hope for patients with advanced heart failure and neuropathy conditions.
Moderna (MRNA) closed up +$2.66 after Friday’s -$2.92, Thursday’s -$2.37, Wednesday’s -$1.33, Tuesday’s +$0.72 and last Monday’s -$4.08 with a positive +$0.11 or +0.28% aftermarket
Negative Indication:
Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed up +$0.07 after Friday’s -$2.26 after Thursday’s -$0.31, Wednesday’s -$0.44, Tuesday’s -$2.41, Monday’s +$3.29 with a negative -$0.41 or -1.70% aftermarket
Regenxbio (RGNX) closed up +$0.52 after Friday’s -$1.51, Thursday’s +$1.16, Wednesday’s +$0.18, Tuesday’s -$1.05 and last Monday’s +$0.40 with a negative -$0.24 or -2.36% aftermarket
The BOTTOM LINE: US stock futures fell on Tuesday as worries about a nuclear escalation to the Russia-Ukraine war rattled markets, stealing focus from Nvidia (NVDA) earnings and other corporate results. <Yahoo Finance>
Been cryin’ a river all last week, this week so far and the wallowing month to date as earnings season ended for my covered companies.
It’s time for the oversold to be recognized, one of my calling cards with words!
Even IF I am early, it’s time even IF some loss …!!
Ranking the end of October:
- 11/18 – Monday closed negative with 14 incliner, 20 decliners and 1 flat
- 11/15 – Friday: closed negative with 4 incliner, 31 decliners and 1 flat
- 11/14 – Thursday: closed negative with 3 incliner, 31 decliners and 1 flat
- 11/13 – Wednesday: closed negative with 8 incliners, 25 decliners and 1 flat
- 11/12 – Tuesday: closed negative with 7 incliner, 27 decliners and 1 flat
- 11/11 – Monday closed positive with 23 incliner, 11 decliners and 1 flat
- 11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
- 11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
- 11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
- 11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
- 11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats
- 11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
